Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

No matter how much she ate, she never felt satisfied. But after starting a non-FDA approved GLP-1 agonist—an injectable drug ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...